Search hospitals > Idaho > Nampa

Saint Alphonsus Medical Center-Nampa

Claim this profile
Nampa, Idaho 83686
Global Leader in Breast Cancer
Global Leader in Breast cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Brain Tumor
104 reported clinical trials
2 medical researchers
Photo of Saint Alphonsus Medical Center-Nampa in NampaPhoto of Saint Alphonsus Medical Center-Nampa in Nampa

Summary

Saint Alphonsus Medical Center-Nampa is a medical facility located in Nampa, Idaho. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Cancer, Brain Tumor and other specialties. Saint Alphonsus Medical Center-Nampa is involved with conducting 104 clinical trials across 185 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.

Area of expertise

1Breast Cancer
Global Leader
Saint Alphonsus Medical Center-Nampa has run 20 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
HER2 negative
2Breast Cancer
Global Leader
Saint Alphonsus Medical Center-Nampa has run 17 trials for Breast cancer. Some of their research focus areas include:
Stage IV
HER2 positive
ER positive

Top PIs

Clinical Trials running at Saint Alphonsus Medical Center-Nampa

Multiple Myeloma
Lung Cancer
Prostate Cancer
Gastric cancer
Laryngeal Cancer
Pancreatic Cancer
Brain Tumor
Breast cancer
Esophageal Adenocarcinoma
Esophageal Cancer
Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Alphonsus Medical Center-Nampa?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security